ArticleBlood advances2022

Assessment of safety and immunogenicity of MHC homozygous iPSC-derived CD34+ hematopoietic progenitors in an NHP model.

Saritha S D'Souza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.